|Chemical and physical data|
|Molar mass||257.311 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Timoprazole is in a class of medications called proton pump inhibitors (PPI) that inhibit gastric acid secretion. While it has never come to market, it was studied early on and is considered to be the "backbone" of the PPI class that succeeded it. This medication has high anti-secretory activity, which flared interest along with its simple structure.
- Snaeder, W. (1996). Drug prototypes and their exploitation. Wiley. pp. 414–5.
- Hemenway, Jeffrey N. (2007). "Case Study: Omeprazole (Prilosec)". Prodrugs. Biotechnology: Pharmaceutical Aspects. pp. 1313–21. doi:10.1007/978-0-387-49785-3_49. ISBN 978-0-387-49782-2.
- Senn-Bilfinger, Jörg; Sturm, Ernst (2006). "The Development of a New Proton-Pump Inhibitor: The Case History of Pantoprazole". Analogue-based Drug Discovery. pp. 115–36. doi:10.1002/3527608001.ch6. ISBN 978-3-527-60800-3.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|